Wuxi Biologics (Cayman) Inc.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipts Repr 0.01 Sh carries a market capitalization of 514.80B, placing it among publicly traded companies globally. Its enterprise value stands at 484.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipts Repr 0.01 Sh's next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipts Repr 0.01 Sh has 160.65B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipts Repr 0.01 Sh maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipts Repr 0.01 Sh's stock has gained approximately 26.18% over the past 52 weeks. The 50-day moving average sits at 5.41, while the 200-day moving average is 4.13.

As of December 31, 2025, WuXi Biologics (Cayman) Inc. Units Thailand Depositery Receipts Repr 0.01 Sh holds 70.63B in cash and equivalents against 13.94B in total debt, resulting in a net debt position of -36.68B. Total book value stands at 212.13B, with working capital of 89.02B providing operational flexibility.